You can predict survival on chemotherapy using the Lymphoma International Prognostic Index. However, this is kind of passe because the agent of choice is now Rituximab, a CD-20 antibody, as it gives superior survival compared to chemotherapy. The dose of Rituximab has to be repeated every 3-6 months.
However, Rituximab only works in 2/3 patients.
Rituximab can rarely reactivate Hepatitis B. Hepatitis serology should be performed on patients receiving Rituximab and prophylaxis with Lamivudine considered for patients with HBsAg.
No comments:
Post a Comment